BioMarin Pharmaceutical Inc. announced on August 31 that it had entered into binding agreements with Ascendis Pharma A/S to resolve a global patent dispute concerning Ascendis’s achondroplasia treatment Yuviwel. The settlement addressed litigation pending across multiple jurisdictions, including a Section 337 investigation by the US International Trade Commission that BioMarin agreed to withdraw. Ascendis confirmed the arrangement the following day, characterizing it as a binding term sheet awaiting finalization of a definitive agreement.
The dispute originated from competing treatments for achondroplasia, a genetic condition affecting bone growth. BioMarin held patents related to the condition and had filed a complaint with the International Trade Commission alleging that Ascendis’s medicine infringed on its intellectual property. Ascendis responded with a declaratory judgment action in California federal court, invoking the regulatory safe harbor provision. The matter proceeded to the US Court of Appeals for the Federal Circuit earlier in the year, with both parties debating procedural issues regarding which forum should have primary jurisdiction.
Under the settlement terms, Ascendis will pay BioMarin royalties of 20% on Yuviwel’s net US sales and 18% on net sales in the European Union, Brazil, and South Korea, retroactive to the drug’s initial commercial launch and continuing through May 20, 2030. In return, BioMarin granted Ascendis a non-exclusive, worldwide, royalty-bearing license for navepegritide, Yuviwel’s active compound, enabling unrestricted continued development and commercialization.
Both companies characterized the outcome favorably. BioMarin’s CEO stated the settlement reinforces the company’s commitment to long-term innovation in rare genetic conditions. Ascendis’s CEO cited Yuviwel’s commercial performance and the drug’s significance in addressing unmet medical needs in achondroplasia and skeletal dysplasias. The resolution eliminates litigation uncertainty for both parties, providing BioMarin with a defined revenue stream while granting Ascendis full commercial flexibility for one of its key products at a critical growth stage.
Analysts noted that while the settlement removes uncertainty, its ultimate value hinges on Yuviwel’s sales trajectory through 2030. BioMarin investors should view the royalty stream as a modest, sustained revenue source rather than a significant growth catalyst. Ascendis investors must assess the drug’s commercial momentum against the royalty burden now embedded in its economics through the settlement period.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI